Cargando…

Psoriasis and Co-morbidity

Psoriasis is associated with multiple co-morbid medical conditions. The purpose of this study is to evaluate the relationships between psoriasis and cardiovascular disease, psoriatic arthritis, mental health conditions, and immune-mediated diseases, respectively. A literature search was performed du...

Descripción completa

Detalles Bibliográficos
Autores principales:	AMIN, Mina, LEE, Erica B., TSAI, Tsen-Fang, WU, Jashin J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Society for Publication of Acta Dermato-Venereologica 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128942/ https://www.ncbi.nlm.nih.gov/pubmed/31971602 http://dx.doi.org/10.2340/00015555-3387

Ejemplares similares

Updates on the Treatment of Erythrodermic Psoriasis
por: Lo, Yang, et al.
Publicado: (2021)

HLA-Cw1 and Psoriasis
por: Huang, Yi-Wei, et al.
Publicado: (2021)

Overlapping Features of Psoriasis and Atopic Dermatitis: From Genetics to Immunopathogenesis to Phenotypes
por: Tsai, Ya-Chu, et al.
Publicado: (2022)

Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy
por: Pithadia, Deeti J., et al.
Publicado: (2019)

Combination Therapy for Psoriasis with Methotrexate and Other Oral Disease-Modifying Antirheumatic Drugs: A Systematic Review
por: Hsieh, Tyng-Shiuan, et al.
Publicado: (2023)

Subcutaneous methotrexate for symptomatic control of severe recalcitrant psoriasis: safety, efficacy, and patient acceptability
por: Manalo, Iviensan F, et al.
Publicado: (2015)

Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence
por: Wu, Jashin J., et al.
Publicado: (2020)

Treatment Response of Patients with Erythrodermic Psoriasis after Switching to Guselkumab
por: Chiang, Cheng-Ying, et al.
Publicado: (2021)

Clinical Efficacy and Safety of Psoriasis Treatments in Patients with Concomitant Metabolic Syndrome: A Narrative Review
por: Merola, Joseph F., et al.
Publicado: (2022)

Exacerbation of Psoriasis Following COVID-19 Vaccination: Report From a Single Center
por: Huang, Yi-Wei, et al.
Publicado: (2021)

Economic Burden of Comorbidities in Patients with Psoriasis in the USA
por: Wu, Jashin J., et al.
Publicado: (2022)

Psoriasis: Epidemiology, clinical features, co-morbidities, and clinical scoring
por: Dogra, Sunil, et al.
Publicado: (2016)

The risk of COVID-19 in patients with psoriasis: A retrospective cohort study
por: Wu, Jashin J., et al.
Publicado: (2022)

Serial QuantiFERON-TB Gold testing in patients with psoriasis treated with ustekinumab
por: Hsiao, Chuan-Yu, et al.
Publicado: (2017)

Effect Modification by Smoking Status on the Association Between Psoriasis and Chronic Obstructive Pulmonary Disease among Adults in the USA
por: LIU, Jeffrey, et al.
Publicado: (2021)

Psoriasis beyond the skin: an expert group consensus on the management of psoriatic arthritis and common co-morbidities in patients with moderate-to-severe psoriasis
por: Strohal, R, et al.
Publicado: (2014)

Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review
por: Thatiparthi, Akshitha, et al.
Publicado: (2021)

Psoriasis & cardiovascular morbidity: The missing links?
por: Ganguly, Satyaki, et al.
Publicado: (2017)

Generalized pustular psoriasis treated with apremilast in a patient with multiple medical comorbidities
por: Jeon, Caleb, et al.
Publicado: (2017)

Remission Duration and Long-Term Outcomes in Patients with Moderate-to-Severe Psoriasis Treated by Biologics or Tofacitinib in Controlled Clinical Trials: A 15-Year Single-Center Experience
por: Huang, Yi-Wei, et al.
Publicado: (2019)

Correction to: Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence
por: Wu, Jashin J., et al.
Publicado: (2020)

The Risk of Chronic Pancreatitis in Patients with Psoriasis: A Population-Based Cohort Study
por: Chiu, Hsien-Yi, et al.
Publicado: (2016)

Concomitant Sleep Disorders Significantly Increase the Risk of Cardiovascular Disease in Patients with Psoriasis
por: Chiu, Hsien-Yi, et al.
Publicado: (2016)

Suboptimal Clinical and Quality of Life Outcomes in Patients with Psoriasis Undertreated with Oral Therapies: International Physician and Patient Survey
por: Thai, Sydney, et al.
Publicado: (2023)

Psychiatric Morbidities and Their Impact on Quality of Life in Patients With Psoriasis
por: Kumar, Abhishek, et al.
Publicado: (2023)

Comorbidities in Chilean patients with psoriasis: a Global Healthcare Study on Psoriasis
por: Valenzuela, Fernando, et al.
Publicado: (2022)

Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement
por: Ger, Tzong-Yun, et al.
Publicado: (2019)

Itraconazole in the Treatment of Nonfungal Cutaneous Diseases: A Review
por: Tsai, Ya-Chu, et al.
Publicado: (2019)

Effectiveness of Biologics, Patient-Reported Outcomes, and Clinical Photography in a Subset of Patients with Moderate-to-Severe Psoriasis: Week 12 Results from the Psoriasis Study of Health Outcomes (PSoHO)
por: Travaglini, Massimo, et al.
Publicado: (2023)

Matching-Adjusted Indirect Comparison of Long-Term Efficacy and Safety Outcomes for Calcipotriol Plus Betamethasone Dipropionate Foam Versus Halobetasol Proprionate Plus Tazarotene Lotion in the Treatment of Plaque Psoriasis
por: Adam, David N., et al.
Publicado: (2022)

Time to Loss of Response following Withdrawal of Ixekizumab in Patients with Moderate-to-Severe Psoriasis
por: PAPP, Kim, et al.
Publicado: (2022)

Psychiatric morbidities and its impact on quality of life in Psoriasis patient.
por: Kumar, Abhishek, et al.
Publicado: (2022)

The MARCOPOLO Study of Ustekinumab Utilization and Efficacy in a Real-World Setting: Treatment of Patients with Plaque Psoriasis in Asia-Pacific Countries
por: Youn, Sang Woong, et al.
Publicado: (2016)

Efficacy and Safety of Spesolimab in Patients with Generalized Pustular Psoriasis: A Subgroup Analysis of Chinese Patients in the Effisayil 1 Trial
por: Tsai, Tsen-Fang, et al.
Publicado: (2023)

A cross-sectional study of psychiatric co-morbidity and quality of life in patients with psoriasis in a tertiary care hospital
por: SupriyaYedve,, et al.
Publicado: (2022)

Assessment of clinical co-morbidities
por: Basu, Debasish, et al.
Publicado: (2018)

A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines
por: Huang, David B., et al.
Publicado: (2004)

Patient Characteristics, Health Care Resource Utilization, and Costs Associated with Treatment-Regimen Failure with Biologics in the Treatment of Psoriasis
por: A. Foster, Shonda, et al.
Publicado: (2016)

Use of H-1 Antihistamine in Dermatology: More than Itch and Urticaria Control: A Systematic Review
por: Hsieh, Chang-Yu, et al.
Publicado: (2021)

Use of Contact Immunotherapy in the Treatment of Skin Diseases Other than Alopecia Areata
por: Lai, Kun-Wei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u7t9nk1ropi2svn21q1p5o9f2f